In this issue:
Trastuzumab deruxtecan in HER2- mutant NSCLC
Erlotinib ±bevacizumab in advanced metastatic EGFR-mutant NSCLC
First-line osimertinib for EGFR-mutant advanced NSCLC
Long-term outcomes in advanced/metastatic NSCLC after ICIs
Gefitinib vs. cisplatin + vinorelbine for resected stage II–IIIA EGFR-mutant NSCLC
First-line atezolizumab in NSCLC: impact of PPIs
Vibostolimab ±pembrolizumab in advanced solid tumours including NSCLC
Second-line osimertinib ±bevacizumab in advanced EGFR T790M-mutated NSCLC
First-generation EGFR-TKIs may affect osimertinib benefits in EGFR T790M-mutant NSCLC
SARS-COV-2 vaccine in thoracic cancer patients
First-line nivolumab + ipilimumab in advanced NSCLC
Please login below to download this issue (PDF)